Glycopeptide Antibiotics Market 2024 – By Size, Share, Growth And Global Forecast Report 2033

Overview and Scope
Glycopeptide antibiotics are a group of antibiotics having structures that either comprise a glycosylated cyclic or polycyclic non-ribosomal peptide, used to inhibit bacterial cell wall formation. They were first discovered from plant and soil bacteria.

Sizing and Forecast
The glycopeptide antibiotics market size has grown strongly in recent years. It will grow from $3.31 billion in 2023 to $3.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%.  The  growth in the historic period can be attributed to increasing antibiotic resistance, rising incidence of infectious diseases, government initiatives, increasing healthcare expenditure, globalization of infectious diseases.

The glycopeptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%.  The growth in the forecast period can be attributed to emerging infectious diseases, increasing geriatric population, continued antibiotic resistance challenges, r&d investments and innovations, expansion of healthcare infrastructure. Major trends in the forecast period include increasing antibiotic resistance, advancements in research and development, global health emergencies driving demand, collaborations for antibiotic stewardship, market expansion in emerging economies.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Segmentation & Regional Insights

The glycopeptide antibiotics market covered in this report is segmented –

1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs

2) By Route of Administration: Oral, Parenteral, Other Routes

3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications

4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

North America was the largest region in the glycopeptide antibiotics market in 2023. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9444&type=smp

Major Driver Impacting Market Growth
The rising number of cancer and infectious disease cases is expected to propel the growth of the glycopeptide antibiotics market going forward. Cancer refers to a disease that occurs when certain body cells multiply beyond their limits and spread to other body regions, whereas, infectious diseases are disorders produced by organisms such as bacteria, viruses, fungus, or parasites. The glycopeptide antibiotics are used to treat a variety of infectious disorders caused by methicillin-resistant staphylococcus aureus, streptococcus, or enterococcus bacteria that are resistant to beta-lactams and other antibiotics. In cancer patients, glycopeptide antibiotics are used to boost radiotherapy’s antitumor effects by eliminating not only the targeted cancer cells but also distant cancer cells farther in the body. For instance, according to the American Cancer Society, a US-based non-profit health organization committed to cancer eradication, in 2022, the US had 1.9 million new cancer cases and 609,360 cancer deaths, for a total of 1,670 fatalities each day. Therefore, the rising cancer and infectious disease cases will drive the growth of the glycopeptide antibiotics market.

Key Industry Players
Major companies operating in the glycopeptide antibiotics market are adopting a strategic partnership approach, aiming to bring life-saving revolutionary antibiotics to the Middle East. Strategic partnerships refer to a process in which companies leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in March 2022, Cumberland Pharmaceuticals Inc., a US-based specialty pharmaceutical company, announced a partnership with Tabuk Pharmaceutical Manufacturing Company. The news follows an agreement between the firms under which Tabuk would have exclusive trademark rights and promote the Vibativ (telavancin) injection for patients in Saudi Arabia, Jordan, and possibly additional Middle Eastern nations. Vibativ is a potentially life-saving medication for patients suffering from ventilator-associated pneumonia and hospital-acquired pneumonia caused by a variety of Gram-positive bacterial infections, including those that are difficult-to-treat and multidrug-resistant. Tabuk Pharmaceutical Manufacturing Company is a Saudi Arabia-based pharmaceutical company.

The glycopeptide antibiotics market report table of contents includes:
1. Executive Summary
2. Glycopeptide Antibiotics Market Characteristics
3. Glycopeptide Antibiotics Market Trends And Strategies
4. Glycopeptide Antibiotics Market – Macro Economic Scenario
5. Global Glycopeptide Antibiotics Market Size and Growth
………………………..
31. Global Glycopeptide Antibiotics Market Competitive Benchmarking
32. Global Glycopeptide Antibiotics Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Glycopeptide Antibiotics Market
34. Glycopeptide Antibiotics Market Future Outlook and Potential Analysis
35. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model